Holen Sie sich die Stockscreener-App
1.32
4.35%
-0.06
Handel nachbörslich:
1.34
0.02
+1.52%
Schlusskurs vom Vortag:
$1.38
Offen:
$1.37
24-Stunden-Volumen:
2.36M
Relative Volume:
0.75
Marktkapitalisierung:
$353.60M
Einnahmen:
$236.20M
Nettoeinkommen (Verlust:
$-5.35M
KGV:
-73.74
EPS:
-0.0179
Netto-Cashflow:
$67.70M
1W Leistung:
+0.00%
1M Leistung:
+3.94%
6M Leistung:
-55.56%
1J Leistung:
-25.42%
1-Tages-Spanne:
$1.32
$1.40
1-Wochen-Bereich:
$1.32
$1.46
52-Wochen-Spanne:
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.32 | 369.67M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy By Investing.com - Investing.com Canada
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance
Aug Sectors: What is the next catalyst for Akebia Therapeutics Inc2026 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D DaySlideshow (NASDAQ:AKBA) 2026-04-04 - Seeking Alpha
Akebia Therapeutics, Inc. (AKBA) stock price, news, quote and history - Yahoo Finance UK
Akebia (AKBA) director granted 214,400 options at $1.41, 3-year vest - Stock Titan
Akebia (NASDAQ: AKBA) director Philip J. Vickers files initial Form 3 - Stock Titan
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Issues Inducement Grants With Stock Options for New Employees - geneonline.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Akebia's Research and Development Day May Confirm or Undermine Its Kidney Treatment Strategy - Bitget
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia gives 13 new hires stock options for 679,900 shares - Stock Titan
AKBA: Vafseo and a robust pipeline drive growth, with major clinical milestones expected by 2027 - TradingView
AKBA: Innovative kidney disease pipeline advances with major clinical and commercial catalysts ahead - tradingview.com
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets - MarketBeat
Akebia Therapeutics Appoints Philip Vickers, Ph.D. to Board of Directors – Company Details and Nasdaq Listing (2026) - Minichart
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - Sahm
Akebia Therapeutics appoints biopharmaceutical leader Philip Vickers to its board of directors - marketscreener.com
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors - TradingView
Akebia Therapeutics adds Philip Vickers to board of directors By Investing.com - Investing.com India
Akebia Therapeutics (AKBA) appoints Philip Vickers to Board as Steven Gilman retires - Stock Titan
Akebia Therapeutics adds Philip Vickers to board of directors - investing.com
AKBA.O PE Ratio & Valuation, Is AKBA.O Overvalued - Intellectia AI
AKBA Should I Buy - Intellectia AI
AKBA.O Technical Analysis & Stock Price Forecast - Intellectia AI
AKBA.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKBA.O Forecast — Price Prediction for 2026. Should I Buy AKBA.O? - Intellectia AI
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Insider Monkey
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
10 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Nordea Investment Management Boosts Stake in Akebia Therapeutics - National Today
Nordea Investment Management AB Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Does Akebia Therapeutics Inc offer margin of safety2026 Top Decliners & Weekly Setup with High ROI Potential - baoquankhu1.vn
Fundamentals Check: What is the earnings history of Akebia Therapeutics IncEarnings Overview Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
US Market Recap: What is the next catalyst for Akebia Therapeutics IncPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Vanguard Disaggregates Holdings; Akebia (AKBA) Beneficial Ownership Reported as 0 - Stock Titan
Aug Retail: Is Akebia Therapeutics Inc stock showing strong momentum2026 Top Gainers & Capital Efficient Trading Techniques - baoquankhu1.vn
Street Watch: Can Akebia Therapeutics Inc benefit from deglobalization2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Downgrade Watch: Should I invest in Akebia Therapeutics Inc before earnings2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
Trend Report: What is the earnings history of Akebia Therapeutics IncRecession Risk & Real-Time Buy Zone Alerts - baoquankhu1.vn
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times
Akebia Announces Approval of Vafseo® (vadadustat) in Australia a - GuruFocus
Is the Options Market Signaling a Surge in Akebia Therapeutics Shares? - Bitget
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Akebia Q2 2025 Earnings Preview - MSN
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akebia Therapeutics Inc-Aktie (AKBA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malabre Richard C | SVP, Chief Accounting Officer |
Feb 02 '26 |
Sale |
1.39 |
49,524 |
68,838 |
299,390 |
| Grund Nicholas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.39 |
84,829 |
117,912 |
561,750 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 02 '26 |
Sale |
1.39 |
67,658 |
94,045 |
948,432 |
| Rucci Carolyn M. | SVP, Chief Legal Officer |
Feb 02 '26 |
Sale |
1.39 |
69,772 |
96,983 |
588,378 |
| Ostrowski Erik | SVP, CFO, CBO & Treasurer |
Feb 02 '26 |
Sale |
1.39 |
34,951 |
48,582 |
672,635 |
| Butler John P. | CEO and President |
Feb 02 '26 |
Sale |
1.39 |
341,305 |
474,414 |
3,206,233 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):